Key facts
- HeartFlow (NAS: HTFL)’s last known valuation is $1.5B (Aug 2025).
- It has raised $1.2B across 2 recorded rounds; the latest was Later Stage VC ($98.4M) in Apr 2025.
- Notable investors include Wellington Management, Bain Capital Life Sciences, Hayfin Capital Management.
- 6 institutional filers report fund marks on HeartFlow (NAS: HTFL) across 55 filings.
- Status: Publicly Held.
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for HeartFlow (NAS: HTFL)
Funding rounds
2 roundsAbout HeartFlow (NAS: HTFL)
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, from which it derives maximum revenue from the United States.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2007
- Employees
- 843
- Website
- heartflow.com/
- Ownership
- Publicly Held
HeartFlow (NAS: HTFL) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HeartFlow (NAS: HTFL) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
6 filers · latest Jun 20266 SEC-registered funds reported 55 fair-value marks on HeartFlow (NAS: HTFL) between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.